Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a Hold rating on Fresenius Medical Care (NYSE:FMS) and lowers the price target from $24 to $22.
July 31, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Fresenius Medical Care and lowered the price target from $24 to $22, indicating a cautious outlook.
The lowered price target from $24 to $22 by Truist Securities suggests a less optimistic view on Fresenius Medical Care's short-term performance, which could lead to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100